Navigation Links
AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
Date:10/5/2009

    UPPSALA, Sweden, October 5 /PRNewswire-FirstCall/ --
    - A New Miniaturized PCR Instrument With SuperConvection(TM)
    - At One Sixth the Price of QuanTyper(TM) Without Loss of Performance
    - Next Generation of PCR Expected to Rapidly Penetrate the Market

AlphaHelix (Ticker: ALPH) has in a very short time developed a miniaturized PCR-instrument - AmpXpress(TM) - to meet demands for lower instrument prices. This was made possible through know-how obtained during the development of QuanTyper(TM). AmpXpress(TM) is substantially smaller in size and weight, silent, consumes less power and will attract customers that are looking for a fast, simple and easy to use PCR-instrument with SuperConvection(TM). AlphaHelix expects a rapid penetration of the market as the price of AmpXpress(TM) is comparable to low-end thermal cyclers (without a rotary format). The sales price of AmpXpress(TM) is only one sixth of the price of QuanTyper(TM) (the first version of AmpXpress(TM) is however a standard PCR instrument, and does not feature real-time detection (qPCR). AmpXpress(TM) will be presented tomorrow at the BIOTECHNICA show in Hannover, Germany.

More information about AmpXpress(TM) is found at http://www.alphahelix.com. The product development has cost approximately 500 KSEK (gross). AlphaHelix has also been granted 250 KSEK by the Swedish Agency for Economic and Regional Growth. A first series of ten instruments has been initiated and patent applications have been submitted.

Technology assessment of SuperConvection and QuanTyper(TM) proceeds at the American biotechnology company and is not affected by the launch of AmpXpress(TM). Results from the evaluation are expected early November, at the earliest.

AlphaHelix Molecular Diagnostics AB (publ) develops instruments for rapid DNA analysis. The company's patented technology enables identification of virus and bacteria faster and with greater sensitivity than other technology available on the market. The AlphaHelix share is traded at AktieTorget http://www.aktietorget.se, which is a multilateral trading facility for small caps under the supervision of the Swedish Financial Supervisory Authority.

SOURCE AlphaHelix Molecular Diagnostics AB


'/>"/>
SOURCE AlphaHelix Molecular Diagnostics AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
3. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
4. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
5. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
6. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
7. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
8. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
9. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):